SBIR-STTR Award

UDP-Glucuronic Acid Regeneration System
Award last edited on: 11/8/06

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$1,066,959
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Inmar Z Munir

Company Information

Biocatalytics Inc

129 North Hill Avenue Suite 103
Pasadena, CA 91106
   (626) 585-9797
   N/A
   www.biocatalytics.com
Location: Multiple
Congr. District: 27
County: Los Angeles

Phase I

Contract Number: 1R43DK067696-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2004
Phase I Amount
$100,000
Glucuronidation is a major metabolic pathway for the inactivation and detoxification of endogenous and exogenous compounds in the human body. Glucuronides are formed by a super family of uridine diphosphoglucuronosyl transverses (UGTs) that convert a number of lipophilic xenobiotics (drugs, steroids, pollutants and pesticides) into more hydrophilic species by linking them to a polar sugar, which are then more readily eliminated from the body. UGTs have been shown to be active toward compounds with a wide variety of chemical structures, such as amines, hydroxylated compounds, and carboxylic acids. Therefore, phase II metabolism (conjugation) is often independent of phase I (functionalization) metabolic pathways, as the vast majority of foreign chemicals (drugs, steroids, pesticides and pollutants) already contain functional groups. This has led to an increasing interest in these metabolites for analytical, pharmacological, and toxicological investigations. Glucuronosyl derivatives of xenobiotic compounds are useful as standards in the analysis of urine or blood samples for illegal drugs, or exposure to biocides. They are also important in studies of the metabolism of new drugs, as metabolites might be more toxic or cause undesirable side effects. More recently, glucuronyl derivatives of pharmacologically active compounds have been investigated as potential prodrugs. As a result, efficient and economical methods for glucuronide production have been sought. While chemical methods are available, they are often unsuitable for a variety of reasons. Consequently, the use of enzymic methods remains to be the desired technique. However, a major limitation for the use of enzymes in the preparative synthesis of glucuronides is the high cost of the co-factor, UDP-glucuronic acid, UDPGA. In phase 1 research, a novel UDGPA regeneration system employing a coupled enzyme system will be developed. This process will enable the UDPGA co-factor to be used in catalytic, rather than stoichiometric amounts, as is the current practice - thus significantly reducing the cost of production.

Thesaurus Terms:
chemical reaction, cofactor, enzyme mechanism, method development, uridine diphosphate glucuronate catalyst, chemical conjugate, detoxification, glucose dehydrogenase, glucuronide, hexosyltransferase, recombinant protein, sucrose, uridine diphosphate Escherichia coli

Phase II

Contract Number: 2R44DK067696-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2005
(last award dollars: 2006)
Phase II Amount
$966,959

Glucuronidation is a major metabolic pathway for the inactivation and detoxification of endogenous and exogenous compounds in the human body. Glucuronides are formed by a super family of uridine diphosphoglucuronosyl transferases (UGTs) that convert a number of lipophilic xenobiotics (drugs, steroids, pollutants and pesticides) into more hydrophilic species by linking them to a polar sugar, which are then more readily eliminated from the body. Glucuronosyl derivatives of xenobiotic compounds are useful as standards in the analysis of urine or blood samples for illegal drugs, or exposure to biocides. They are also important in studies of the metabolism of new drugs, as metabolites might be more toxic or cause undesirable side effects. More recently, glucuronyl derivatives of pharmacologically active compounds have been investigated as potential prodrugs. As a result, efficient and economical methods for glucuronide production have been sought. The two main limitations for the preparative production of glucuronides needed as analytical standards are (1) the high cost of the UDP-glucuronic acid (UDPGA) co-factor and (2) the lack of availability and the relative instability of the human UGT isoforms, themselves. The former problem was resolved in the Phase I sponsored research, in which an efficient method was developed for the regeneration of UDPGA using a coupled enzyme method, thus reducing the cost of glucuronide production significantly. However, the lack of availability of the human UGTs remains to be a problem, as a result of the low yields produced in the baculovirus-infected insect cells currently used. In Phase II, we intend to solve the latter problem, by cloning and expressing 5 different UGT isozymes in E. coll., using our patented method for gene redesign and synthesis. To date, we have used this proprietary method to produce 7 human cytochromes with high activity at quantities not previously commercially available. We intend use the knowledge gained from this to clone, express and produce human UGTs 1A1, 1A4, 1A6, 1A9 and 2B7 in the amounts necessary for the efficient synthesis of glucuronides at the preparative level